The prevalence of valvular heart diseases (VHD) is rising in the U.S., with more than 5 million Americans diagnosed each year. While up to 1.5 million people suffer from aortic stenosis (AS) in the U.S., approximately 500,000 within this group of patients suffer from severe AS. Additionally, an estimated 4 million people have significant mitral valve insufficiency, with an annual incidence of 250,000 suffering from mitral regurgitation (MR) in the U.S.
The ACC launched the Managing Aortic Stenosis (MAS) and Emerging Mitral Regurgitation Clinical Care (EMC2) initiatives to improve valvular care through appropriate diagnosis, referral and treatment, particularly with the introduction of new valve technologies. MAS and EMC2 are multidisciplinary efforts with various components to create awareness and resources for clinicians and patients to better understand and overcome the gaps in knowledge and care for AS and MR. These components include:
- Evolving Valve Management Strategies Roundtables: These meetings bring together experts from a variety of medical specialties, organizations, industry, patient groups and other stakeholders. The goal is to draw on the collective experience and wisdom of participants to address the common challenges faced in identifying, managing and treating AS and MR.
- Valvular Heart Disease Clinical Topic Collection: A page dedicated to VHD that features relevant news articles, case challenges, and clinical resources.
- Clinical Tools for MAS and EMC2: Practical tools developed to further aid clinicians in the decision making process for the assessment and management of AS and MR.
- Patient Resources for MAS and EMC2: Educational materials and tools developed to increase patient engagement and improve the patient-clinician dialogue.
The overall Valvular Heart Disease Initiatives are supported by Founding Sponsors Abbott Vascular and Edwards Lifesciences.
Support for the Evolving Valve Management Strategies Roundtable was provided by Abbott Vascular, Edwards Lifesciences and Medtronic.